FR2859910A1 - Treating and/or preventing benign prostatic hypertrophy, using 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol to induce apoptosis in prostate cells - Google Patents

Abstract

The use of 1alpha -fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol (I) or its salt or ester (I') is claimed in the production of medicaments for the treatment and/or prophylaxis of benign prostatic hypertrophy (BPH), (I)/(I') optionally being used in combination with a second anti-BPH agent (II). The use of 1alpha -fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol (I) or its salt or ester (I') is claimed in the production of medicaments for the treatment and/or prophylaxis of benign prostatic hypertrophy (BPH), (I)/(I') optionally being used in combination with a second anti-BPH agent (II) (administered separately, sequentially or simultaneously in the same formulation or a different formulation). Independent claims are included for: (1) corresponding formulations for treating BPH; and (2) pharmaceutical formulations (A) (with no restriction on use) comprising (I) dissolved in fractionated coconut oil, optionally together with preservative(s). ACTIVITY : Cytostatic; Uropathic; Antipsoriatic; Antiseborrheic; Dermatological; Osteopathic. MECHANISM OF ACTION : Apoptosis inducer.

Description

<Desc / Clms Page number 1>

COMPOUND AND USE AS A TREATMENT
The present invention relates to the use of 1α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol (compound A) for the manufacture of a medicament for the prevention and / or treatment of benign prostatic hyperplasia (BPH) and associated symptoms. It also relates to a method for preventing and / or treating benign prostatic hyperplasia and related symptoms by administering 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomic acid. 20-epicholecalciferol in an amount effective to prevent and / or treat such a disease alone or in combination with other active agents.

 BPH is a common disorder in older men, occurring in approximately 50% of men aged 60 and 90% of men aged 85 years. BPH is a specific histopathological entity characterized by hyperplasia of stromal and epithelial cells.

 For more than a century, the two known etiological factors for the pathogenesis of BPH have been aging and the presence of functional testes. However, as prostate science progresses, this concept becomes unsatisfactory as it does not cover all aspects of the pathogenesis of BPH. Additional etiological factors play a significant role in regulating prostate growth. In particular, it has become apparent that growth of the prostate is under the immediate control of specific growth factors produced by prostatic cells, acting locally on adjacent cells in a paracrine mechanism or on the same cells in an autocrine mechanism. Therefore, a large effort is currently being made to identify therapeutic strategies to inhibit intraprostatic growth factors.

<Desc / Clms Page number 2>

 BPH is a common cause of chronic lower urinary tract symptoms that can affect the filling (irritating symptoms) and discharge (obstructive symptoms) phases of the urination cycle. These symptoms affect the social, psychological, domestic, professional, physical and sexual life of patients and lead to a profound and negative impact on their quality of life. In addition to this, BPH may cause more acute urologic complications, particularly acute urinary retention (URA), often considered to be the most serious complication of BPH and less frequently recurrent urinary tract infections. dilation of the upper urinary tract, the formation of stones in the bladder and recurrent hematuria.

 Management of BPH is associated with extremely high social costs estimated at $ 4 billion in 1993 and is projected to be $ 26 billion in 2003 alone in the United States.

 Current medical therapy for BPH is the oral administration of recently accepted FDA-accepted inhibitors of 5-alpha-alpha-reductase (finasteride and dutasteride) and al (terazosin, doxazosin, tamsulosin as well as silodosin, AIO-8507L, RBx-2258 etc.). Each of these therapeutic options is associated with advantages and disadvantages regarding their different mechanisms of action. While al receptor antagonists are very effective in reducing symptoms related to lower urinary tract symptoms (STUI), they are ineffective in reducing prostate volume and therefore in avoiding BPH-related surgery.

Conversely, 5-a-reductase inhibitors such as finasteride and dutasteride, by decreasing the formation of dihydrotestosterone (DHT), reduce the size of the prostate and the need for surgery. In addition, the results

<Desc / Clms Page number 3>

 Recent studies of the seven-year Prostate Cancer Prevention Trial (PCPT), which involved more than 18,000 healthy older men, have shown that finasteride can prevent or delay prostate cancer. occurrence of prostate cancer (see Thompson IM, et al., New England Journal of Medicine (2003) 349, p 215-224).

However, as expected (see Kassabian VS, Lancet (2003) 361 p 60-62), finasteride was not free of anti-androgenic adverse effects on sexual function, such as sexual efficacy decreased sexual desire and gynecomastia, which significantly weakens its attractiveness as a cancer preventive agent.

In addition, finasteride treatment has been associated with increased detection of high-grade prostate cancer, possibly because the weakly androgen-induced state of finasteride has selected malignant growth-stage malignant cells. most aggressive androgenic effect (see Scardino PT, New England Journal of Medicine (2003) 349 p 297-299).

 Thus, needs have not been met for a new class of drugs for medical therapy of BPH, which should be able to prevent acute urinary retention, as well as the need for surgery related to it, by decreasing androgen-induced prostatic growth but without directly interfering with the androgen receptors (AR), and therefore without adverse anti-androgenic effects in the prostate and outside the prostate, for example, side effects at the sexual level. Such drugs, by disrupting the signals of intraprostatic growth factors, could be useful not only for treating BPH but also for preventing prostate cancer, possibly without having to select malignant clones insensitive to AR.

<Desc / Clms Page number 4>

 As described herein, the inventors have determined that the well-tolerated non-hypercalcemic vitamin D3 analog, 1- [alpha] -fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20- Epi-cholecalciferol (Compound A) is a prime example of such a drug because it can act against BPH in a way that is independent of the androgen receptor by targeting multiple pathways that control the growth of BPH cells. including growth factor-induced prostate proliferation.

 1,25-Dihydroxyvitamin D3 [1,25 (OH) 2D3], the activated form of vitamin D3, is a secosteroid hormone that not only plays a central role in bone and calcium metabolism but is also involved. in the regulation of the immune response and in the differentiation and apoptosis of many types of cells, including malignant cells.

 However, a problem with the therapeutic use of calcitriol is its natural ability to induce hypercalcemia and hyperphosphatemia. Therefore, calcitriol analogues maintaining biological activity but free of hypercalcemic side effects have been developed.

 US 5,939,408 and EP808833 disclose a number of 1,25 (OH) 2D3 analogs comprising the compound 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20 epi-cholecalciferol (compound A). U.S. Patent Nos. 5,939,408 and EP808833 disclose that the compounds induce differentiation and inhibition of proliferation in various skin and cancer cell lines and are useful for the treatment of hyperproliferative skin diseases such as psoriasis, neoplasms and the like. plastics such as leukemia, breast cancer and sebaceous gland diseases such as acne and seborrheic dermatitis and osteoporosis.

 It has now been found, surprisingly, in several studies carried out by the inventors that, at the

<Desc / Clms Page number 5>

difference of some other analogues of 1,25 (OH) 2D3, the analogous compound of 1,25 (OH) 2D3, compound A:

Compound A significantly reduced the growth of human BPH cells in vitro by inducing their apoptosis and reduced prostate growth in vivo, without effects on testosterone and dihydrotestosterone levels. In addition, this inhibition of prostate growth is achieved at non-hypercalcemic doses. Thus, compound A is an effective pharmacological agent for the treatment of benign prostatic hyperplasia.

 As described by the examples mentioned here, compound A reduces the size of the prostate. In addition, as observed with finasteride, compound A prevents the proliferative activity in vitro and in vivo of testosterone. Significantly however, and unlike finasteride, compound A does not inhibit 5-a-reductase type 1 or type 2 activity and can prevent not only the growth of B-cell-induced testosterone but also that induced by dihydrotestosterone. These anti-androgenic properties of compound A are independent of the interaction with AR, as shown by the fact that compound A can not bind to RA, or can act as an agonist or antagonist of RA. RA. In addition, compound A does not affect the secretion of sex hormones. In addition, in our studies, compound A has no significant effect

<Desc / Clms Page number 6>

 on the PSA levels, it appears that there is no danger of treatment with compound A, thus masking this important indicator of possible prostate cancer.

 Another significant benefit of compound A is that in vitro studies have revealed that this drug, unlike finasteride, is able to inhibit basic and testosterone-stimulated growth of bladder cells and is expected to it is useful in the prevention and / or treatment of bladder dysfunction in humans. In vivo studies in a validated model of bladder neck obstruction in the bladder dysfunction rat also demonstrated the beneficial effect of compound A.

This result is significant because bladder dysfunction is a common and troublesome sequel to BPH. Thus compound A is able to reduce the size of the prostate and improve bladder dysfunction i.e. to improve bladder function and bladder-related BPH symptoms at the same time by a direct effect of compound A on both the prostate and the bladder. This effect can be expected to go beyond the improvement in bladder symptoms that would simply be expected as a result of the reduction in prostate size. Symptoms of the bladder include overactive bladder and indicators of improved bladder function include reduction of bladder contractions and post-voiding residue.

 Thus, the present invention provides the use of 1- [alpha] -fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol for the manufacture of a medicament for the prevention and / or treatment of benign prostatic hyperplasia. Also within the scope of the invention are esters and pharmaceutically acceptable salts of compound A.

 The invention thus proposes the use of 1-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi

<Desc / Clms Page number 7>

 cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the prevention and / or treatment of benign prostatic hyperplasia.

 The invention also provides a method for preventing and / or treating benign prostatic hyperplasia, in patients in need of such prevention or treatment, comprising administering a therapeutically effective amount of 1-afluoro 25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol or a pharmaceutically acceptable salt or ester thereof.

 The invention also provides the use of 1α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the prevention and / or treatment of benign prostatic hyperplasia.

 The invention also provides 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for use in the prevention and control of / or the treatment of benign prostatic hyperplasia.

 The invention also provides the use of 1-a-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi cholecalciferol, or a pharmaceutically acceptable salt or ester thereof. it, for the prevention and / or treatment of benign prostatic hyperplasia without anti-androgenic adverse effects in the prostate and outside the prostate. It also proposes a method for preventing and / or treating benign prostatic hyperplasia without anti-androgenic effects in the prostate and outside the prostate, in patients in need of such prevention. or treatment, comprising administering a therapeutically effective amount of 1-α-fluoro-25-hydroxy-

<Desc / Clms Page number 8>

 16,23E-diene-26,27-bishomo-20-epi-cholecalciferol or a pharmaceutically acceptable salt or ester thereof.

 The invention also provides the use of 1-a-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi cholecalciferol, or a pharmaceutically acceptable salt or ester thereof. it, for the prevention and / or treatment of benign prostatic hyperplasia and, concomitantly, the prevention and / or treatment of bladder dysfunction. It also proposes a method for preventing and / or treating benign prostatic hyperplasia with prevention and / or concomitant treatment of bladder dysfunction, in patients in need of such prevention or treatment, comprising administering a therapeutically effective amount of 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol or a pharmaceutically acceptable salt or ester thereof; -this.

 1-α-Fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol is a known compound and its preparation is described in US Pat. No. 5,939,408, the description of which is incorporated here by reference.

 Esters include pharmaceutically acceptable labile esters that can be hydrolysed in the body to release compound A.

 The salts of compound A include adducts and complexes which can be formed with alkali and alkaline earth metal ions such as sodium, potassium and calcium ions and salts thereof such as calcium chloride calcium malonate and the like.

 Compound A, or a salt or an ester thereof, may be used alone or it may be administered in combination with known HBP-active agents, for example, an α-receptor blocking agent. -adrenergic agent such as an α-receptor antagonist (e.g., terazosin,

<Desc / Clms Page number 9>

 doxazosin, or tamsulosin or silodosin, AIO-8507L or RBX-2258) or a 5-cxreductase inhibitor (e.g., finasteride or dutasteride). The term "BPH active agent" includes those agents capable or known to have activity for the treatment or prevention of BPH such as the above-mentioned exemplary substances. The combined agent in combination can be mixed with compound A or its salts or esters in various ratios and can be administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art. The combination of A with two or more HBP-active compounds, for example, 3 may be envisioned, for example, a combination with an α1-receptor antagonist and a 5-α-reductase inhibitor.

When administered in combination with the compound A (or a salt or an ester) the combined agent (s) may be used at doses lower than those used when the combined agent in combination is administered alone, perhaps even a dose that is below the therapeutic level when administered alone.

 Thus the invention also provides the use as defined above wherein the drug is administered separately, sequentially or simultaneously in separate pharmaceutical formulations or in combination with a second active agent against BPH.

 Thus, the invention also provides the use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester of the latter, in combination with a second active agent against BPH for the manufacture of a medicament for the prevention and / or treatment of benign prostatic hyperplasia.

<Desc / Clms Page number 10>

 The invention also provides a method for preventing and / or treating benign prostatic hyperplasia in patients in need of such prevention or treatment comprising administering a therapeutically effective amount of 1-a- fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol or a pharmaceutically acceptable salt or ester thereof separately, sequentially or simultaneously in separate pharmaceutical formulations or in combination with a second active agent against BPH.

 The combinations referred to above may conveniently be presented for use as a pharmaceutical formulation. The pharmaceutical formulations thus produced also represent one aspect of the invention.

 The dosage levels and the response time of the administration of the active substances in the pharmaceutical formulations of the invention can be changed to obtain an amount of the active substance that is effective in achieving the desired therapeutic response for a particular patient. , a composition, and a mode of administration, without being toxic to the patient.

An exemplary dose range of Compound A is from 0.1 to 300 grams per day, for example, 50 to 150 grams per day, for example, 75 or 150 grams per day. A unit dose formulation preferably contains 50 to 150 g, for example, 75 or 150 g, and is preferably administered once a day.

 Specifically, a preferred dose of Compound A is the maximum dose that a patient can tolerate and to which he will not develop hypercalcemia or other undesirable side effects such as hypercalciuria. Compound A is preferably administered at a concentration of about 0.001 g to about 100 g per kilogram of body weight, about 0.001 to about 10 g / kg or about 0.001 g to about 100 g / kg of body weight. The ranges

<Desc / Clms Page number 11>

 Intermediates lower than the values mentioned are also intended to form part of the invention.

 As noted above, compound A may be administered in the form of a pharmaceutically acceptable salt or ester thereof, however, compound A is preferably used as it is; it is not used in the form of an ester or a salt thereof.

 This assay can be provided in a conventional pharmaceutical formulation by single administration, by multiple applications, or by controlled release, as needed to obtain the most effective results, preferably once or twice daily (particularly a daily dose). ) for example, orally. In certain situations, periodic dosing may be appropriate to achieve the desired therapeutic response.

 The choice of the exact dose and formulation and the most appropriate mode of delivery will be influenced by, inter alia, the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and the mental acuity of the recipient.

 Representative modes of delivery include the oral, parenteral (including subcutaneous, intramuscular and intravenous), rectal, oral (including sublingual), pulmonary, transdermal, and intranasal routes, most preferably orally. Administration may be continuous or intermittent (for example, by rapid injection).

 The invention also provides a pharmaceutical composition comprising 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier for the prevention and / or treatment of benign prostatic hyperplasia.

<Desc / Clms Page number 12>

 The invention also provides a packaged formulation which contains a pharmaceutical composition comprising 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester and a pharmaceutically acceptable carrier packaged with an instruction for the treatment of benign prostatic hyperplasia.

 As mentioned above, such compositions may be prepared for parenteral (subcutaneous, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for oral or oral administration, particularly in the form of tablets or capsules; for pulmonary or intranasal administration, particularly in the form of powders, nasal drops or aerosols; and for rectal or transdermal administration.

 The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example as described in the Remington article, Pharmaceutical Sciences, 17th Edition, Mack Publishing. Company, Easton, PA, (1985). Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, vegetable oils, naphthalenes hydrogenated and similar products. Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use as nasal drops or metered dose inhaler. For oral administration typical excipients include sugars, calcium stearate,

<Desc / Clms Page number 13>

 magnesium stearate, pregelatinized starch, and the like.

 The orally administrable compositions may comprise one or more physiologically compatible carriers and / or excipients and may be in solid or liquid form. Tablets and capsules may be prepared with binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or poly-vinylpyrollidone; fillers, such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants, such as magnesium stearate, talc, polyethylene glycol, or silica; and surfactants, such as sodium lauryl sulphate. The liquid compositions may contain conventional additives such as suspending agents, for example, sorbitol syrup, methylcellulose, sugar syrup, gelatin, carboxymethylcellulose, or edible fats; emulsifiers such as lecithin, or acacia; vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil; preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). The liquid compositions may be encapsulated in, for example, gelatin to provide a unit dosage form.

 Preferred solid oral dosage forms include tablets, hard shell capsules and soft and elastic gelatin capsules (SEGs). SEG capsules are of particular interest because they provide distinct advantages over the other two forms (see Seager, H., "Soft gelatin capsules: solution to many tableting problems", Pharmaceutical Technology, 9, (1985)). Some of the advantages to using SEG capsules are: a) the uniformity of the dose content is optimized in the SEG capsules because the drug is dissolved or dispersed in a liquid that

<Desc / Clms Page number 14>

 can be dosed in capsules precisely; b) drugs formulated as SEG capsules show good bioavailability because the drug is dissolved, solubilized or dispersed in a water-miscible or oily liquid and so once released into the body the solutions dissolve or are emulsified to produce drug dispersions having a high active area; and c) the degradation of drugs that are sensitive to oxidation during long-term storage is avoided because the dry shell of the soft gelatin provides a barrier against the diffusion of oxygen.

 The dry shell formulation typically comprises a gelatin concentration of about 40% to 60%, a plasticizer concentration (such as glycerine, sorbitol or propylene glycol) of about 20% to 30% and a concentration of in water of about 30 to 40%. Other materials such as preservatives, dyes, opacifiers and flavors may also be present. The liquid filling material comprises a solid drug which has been dissolved, solubilized or dispersed (with suspending agents such as beeswax, hydrogenated castor oil or polyethylene glycol 4000) or a liquid medicine in vehicles or combinations of carriers such as mineral oil, vegetable oils, triglycerides, glycols, polyols and surfactants.

 In an exemplary formulation, the soft gelatin capsules are white, opaque and oval size 2 gelatin capsules containing a liquid filler comprising the active ingredient, compound A, dissolved in Miglyol 812 (acid triglyceride). C8-C12 fatty acids from fractionated coconut oil) with butylated hydroxytoluene (BHT), and butylated hydroxyanisole (BHA), as preservatives. The soft gelatin capsules can be formulated to contain between 0.01 and 25 mg, for example, 75 or 150 g of compound A. The capsules of

<Desc / Clms Page number 15>

 Soft gelatine should be stored at 2 to 8 C and protected from light.

 Formulations containing compound A, or a pharmaceutically acceptable salt or ester thereof, optionally in combination with a second BPA active agent, may be prepared by mixing the ingredients.

 The formulations are preferably prepared under nitrogen and in orange light.

The present invention is now described by means of the following nonlimiting examples, with reference to the figures, in which:
Figure 1 shows the inhibition of proliferation of BPH cells by calcitriol and compound A ("Cmpd A"). Panel A shows that incubation for 48 h with increasing concentrations (10-18 to 10-7 M) of calcitriol (circles) or compound A (squares) resulted in significant and dose dependent inhibition of growth of BPH cells (* P <0.01 relative to the control).

The ALLFIT analysis indicates that both secosteroids share the same maximal inhibition (Imax = 43 1%), but show a marked difference in activity (-logICso for compound A = 15.8 ~ 0.3; logICso for calcitriol = 10.2 0.6, P <0.005). The results are expressed in% inhibition (mean SEM) relative to their relative controls in 3 different experiments performed in triplicate. Panel B shows the effect of increasing concentrations (10-18 to 10-7 M) of compound A on proliferation of T-stimulated BPH cells (10 nM, squares), KGF (10 ng / ml, circles) or (1-3) IGF-I (10 ng / ml, triangles). Compound A induces a significant inhibition (* P <0.01 compared to cells treated with T or GF) of the growth of BPH cells also in the presence of all the stimuli tested with an Imax = 66.6 7.3 % similar.

However, Compound A was more effective at inhibiting the effect of T (-logICso = 16.4 0.6) than

<Desc / Clms Page number 16>

 two other GF, (-logICso of Des (1-3) IGF-I - 12.7 0.6, and -logICso of KGF = 14.2 0.6, P <0.0001). The results are expressed in% of the variation (mean SEM) relative to the maximum stimulation in 3 different experiments performed in triplicate.

Figure 2 shows the effect of compound A, cyproterone acetate and finasteride on the growth of androgen-stimulated BPH cells. BPH cells were incubated for 48 h with compound A (1 nM) or antiandrogens (finasteride, F, 1 nM, cyproterone acetate, Cyp, 100 nM) in the presence of T (10 nM). nM, panel A) or DHT (10 nM, panel B). The results obtained for unstimulated HBP cells are also shown (panel A). The results are expressed in% of the variation (mean SEM) relative to their relative controls in three different experiments performed in four copies. Compound A and cyproterone acetate significantly blocked T- and DHT-induced growth, whereas finasteride was only effective against T. * P <0.01 compared to the control; P <0.01 compared to androgen treated cells.
Figure 3 shows that compound A lacks agonist or antagonistic properties on human AR. The AR-deficient PC3 cell line stably transfected with human AR was transferred to a 24-well plate with a density of 2 x 104 cells / well. After 24 h, the cells were transfected with the AR adapted plasmid pLSPP and, 48 h later, the cells were incubated with increasing concentrations of DHT (squares) or compound A (circles) (panel A) , or with a fixed concentration of DHT (3 nM) in the presence of bicalutamide (squares) or compound A (circles) (panel B) for 18 h. The results (the average of three transfection experiments) are expressed as a percentage of bioluminescence per g of total

<Desc / Clms Page number 17>

 proteins. In order to evaluate the agonist activity, a 100% activity against luciferase was fixed in the presence of 100 nM DHT (panel A), whereas in order to examine the antagonist activity an activity 100% against luciferase was fixed with DHT at 3 nM (panel B).

 Figure 4 shows the inhibition of ventral prostate growth in rats by compound A or finasteride. Panel A: Castrated rats, injected with T-enanthate (30 mg / kg / week), were orally treated for 5 days / week for two consecutive weeks with a vehicle or with increasing doses of Compound A (10.30, 100 and 300 g / kg) or finasteride (F, 10 and 40 mg / kg). The weight of the ventral prostate is expressed in% of the variation (mean SEM) of the weight of the intact, vehicle-treated rats, (p <0.05, * P <0.01 compared to control rats, P < 0.01 relative to the rats to which T was added). Panel B: intact adult rats were orally treated for one month (5 times / week for a total of 27 administrations) with vehicle (control) or increasing concentrations of compound A (10.30, 100 and 300 g / kg ) or finasteride (F, 10 and 40 mg / kg). The weight of the ventral prostate is expressed in% of the variation (mean SEM) of the weight of the control rats, treated by the vehicle (* P <0.01 compared to the control rats).

 Figure 5 shows the effect of compound A and finasteride on clusterin gene expression in the rat ventral prostate. Panel A: Northern analysis of clusterin mRNA expression in the ventral prostate of intact (line 1) or orchidectomized (line 2) rats treated with a vehicle. Lanes 3 to 6 represent clusterin gene expression in orchidectomized rats to which T-enanthate (30 mg / kg) was added for two weeks and treated orally with a vehicle (lane 3). compound A (300 g / kg, line 4 and

<Desc / Clms Page number 18>

 100 g / kg, line 5) or finasteride (40 mg / kg, line 6). Each line was loaded with 10 g of total RNA.

The corresponding expression of GAPDH and the ethidium bromide staining of the gel are shown below the stain. The task is representative of two separate experiments. Panel B: Northern analysis of clusterin mRNA expression in the ventral prostate of intact adult rats treated orally for 1 month (5 times / week, 27 administrations) with a vehicle (line 1), increasing concentrations of compound A (10.30 g / kg, line 2 and 3) or finasteride (40 mg / kg, line 4). Each line was loaded with 10 g of total RNA. The corresponding expression of GAPDH and the ethidium bromide staining of the gel are shown below the stain. The task is representative of two separate experiments.

 Figure 6 shows the morphological effects of compound A on the ventral prostate of castrated rats and to which were added T. Panels A, B, C and E. Representative fields obtained from whole gland transverse sections of the prostate applied immunostaining with a monoclonal antibody against rat clusterine and counterstaining with hematoxylin. In rats treated with castrated vehicles 4 days earlier, clusterin labeling was detectable in the cytoplasm of atrophic cuboidal epithelial cells (panel A, 10x). After two weeks of T (panel B, 10x) supplements, almost all clusterin labeling has disappeared. Conversely, clusterin-positive cells were still present in T-treated rats and different doses of compound A (100 g / kg, panel C, 300 g / kg, panel E, black arrows). Panels D and F show sections consecutive to those used in panels C and E, to highlight DNA fragmentation as assessed by the TUNEL final labeling test by terminal deoxynucleotidyl transferase (TdT).

<Desc / Clms Page number 19>

Two weeks of treatment (9 administrations) with compound A (100 g / kg, panel D, 300 g / kg, panel F) induced massive apoptosis of the majority of epithelial and stromal cells. It should be noted (black arrows), that all clusterin-positive cells have undergone apoptosis, while a substantial portion of clusterless cells also show nuclear fragmentation.

 Figure 7 shows the morphological effects of compound A and finasteride on the prostate of intact adult rats. Panels A, B, D, E, F, and H. Representative fields obtained from cross-sections of whole prostate glands immunostained with monoclonal antibody to rat clusterine and counterstaining with hematoxylin. In Panel A (10x) the primary antibody was omitted. Panel B (10x) shows that in untreated adult rats, only a few scarce epithelial cells were labeled in certain glands (black arrows). Conversely, in the prostate glands of rats treated with increasing concentrations of compound A, cubic epithelial cells characterizing atrophy were stained with clusterin as a function of dose (see black arrows, 10 g / kg, panel D; 30 g / kg, panel E, 100 g / kg, panel F, 10x). Similar results were obtained with finasteride (40 mg / kg, panel H, 10x). Panels C, G and I show periodic consecutive slices, to those shown in panels B, D and F, respectively, to highlight DNA fragmentation as assessed by TUNEL labeling assay by terminal deoxynucleotidyl transferase (TdT). It should be noted (black arrows), that all clusterin-positive cells have undergone apoptosis, while a substantial portion of clusterless cells also show nuclear fragmentation.

<Desc / Clms Page number 20>

 Figure 8 shows the results of a chronic toxicity study in dogs. An apparent reduction in prostate weight is shown after 9 months of treatment with compound A versus placebo.

 Figure 9 shows the results of a chronic toxicity study in dogs. A reduction in the weight of the prostate after healing using a treatment with compound A compared to a placebo.

Figure 10 shows the effect of compound A on testosterone-stimulated cell growth of the bladder. "hB" = human bladder
Figure 11 shows the effect of compound A and other comparator compounds on stimulated and basic bladder cell growth. "T 10 nM" = testosterone; F 1nM "= finasteride.

 Figure 12 shows the effect of a vitamin D compound on the weight of the bladder.

 Figure 13 shows the effect of a vitamin D compound on the frequency of spontaneous bladder contractions.

 Figure 14 shows the effect of a vitamin D compound on the amplitude of spontaneous bladder contractions.

 Figure 15 shows the effect of a vitamin D compound on the pressure of urination.

 Figure 16 shows the effect of a vitamin D compound on the post-voiding residue.

 Figure 17 shows the effect of a vitamin D compound on the contractile response of bladder bands to EFS (electrical stimulation).

EXAMPLES EXAMPLE 1 Effects of Compound A on In Vitro BPH Cells Materials and Methods Materials

<Desc / Clms Page number 21>

Minimum essential medium (MEM), DMEM-F12 mixture 1: 1, Ham F12 medium, phosphate buffered saline (PBS), fraction V bovine serum albumin (BSA), glutamine, geneticin , collagenase type IV, vitamin D3, testosterone (T), dihydrotestosterone (DHT), cyproterone acetate, reduced form of nicotinamide adenine dinucleotide 3'-phosphate (NADPH), dithiothreitol (DTT ), phenylmethylsulfonyl fluoride (PMSF) and a kit for measuring serum calcium were purchased from Sigma (St. Louis, MO). The protein measurement kit was obtained from Bio-Rad Laboratories, Inc. (Hercules, CA). Fetal bovine serum (FBS) was purchased from Unipath (Bedford, UK). Rat-specific anti-clusterin monoclonal antibody (mouse monoclonal IgG) was purchased from UPSTATE Biotechnology (Lake Placid, NY). The Apop Tag Kit for In Situ Terminal Marking (ISEL) was obtained from Oncor (MD, USA). CHO 1827 and CHO 1829 cells were provided by Serono International (Geneva, Switzerland).

Instagel Plus was purchased from Packard (St Louis, MO). Finasteride (pure substance) (17ss- (N, t-butyl) carbamoyl-4-aza-5a-androst-1-en-3-one) was kindly offered by Merck Sharp and Dohme Research Laboratories (Rahway, NJ) . Bicalutamide was kindly offered by AstraZeneca (AstraZeneca, Milan, Italy). The analog 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol (compound A) was provided by Bioxell (Bioxell, Milan, Italy). The keratinocyte growth factor (KGF) was obtained from Pepro Tech EC (London, England) and the insulin-like growth factor type 1, human [Des (1-3) IGF-I] been purchased from GroPep Limitated (Adelaide, Australia). The POD in situ cell death detection kit for TUNEL terminal deoxynucleotidyl transferase (TdT) labeling was obtained from Roche Diagnostics Corporation (Indianapolis, IN). The

<Desc / Clms Page number 22>

 Plastic items for cell cultures were purchased from Falcon (Oxnard, CA). Disposable filtration units for the preparation of growth media were purchased from PBI International (Milan, Italy). Lipofectamine 2000 and Opti-MEM I medium for luciferase transfection were obtained from Invitrogen, Life Technologies (San Giuliano Milanese, Milan, Italy).

Thin layer chromatography silica plates were obtained from Merck (Darmstad, Germany). Testosterone enanthate (T-enanthate) was obtained from Geymonat (Anagni, Italy). The total testosterone detection kit Coat-A-Count was purchased from Medical System (Genova Struppa, Italy). Luteinizing hormone (rLH) [125I] assay systems were obtained from Amersham Pharmacia Biotech (Piscataway, NJ).

BPH cells
Human BPH cells, prepared, maintained, and used as previously described in Crescioli C, et al. Journal of Clinical and Endocrinology Metabolism (2000) 85 p 2576-2583, were obtained from prostate tissues derived from 5 patients, who underwent a suspubian adenomectomy for BPH, after informed consent and approval by the Ethics Committee. local. Patients received no pharmacological treatment in the 3 months prior to surgery.

CHO-1827 and CHO-1829 cell lines transfected with 5-a-reductase
CHO-1827 and CHO-1829 cells, transfected with 5-alpha-reductase 5 (5 [alpha] R-1) or type 2 (5aR-2), respectively (see Steers W. Urology (2001) 58 p 17-24) were maintained in Ham F12 medium supplemented with 5% FCS.

PC3 cell lines transfected by AR
Prostate adenocarcinoma PC3 human cells stably transfected with plasmid p5HbhAR-A containing the human androgen receptor

<Desc / Clms Page number 23>

 (hAR) as previously described (see Bonaccorsi L, et al., Endocrinology (2000) 141 p 3172-3182), were grown in 75 cm 2 culture flasks in Ham F12 medium containing 50 g / ml of geneticin , 10% FCS, penicillin (100 U / ml) and streptomycin (100 mg / ml).

HBP fabric
Prostate tissues for a fixation test were obtained from patients who underwent a suspubenous adenomectomy for BPH. No pharmacological treatment was performed in the 3 months prior to surgery. After the surgery, the tissues were immediately placed in liquid nitrogen and stored at -80 ° C until treatment.

Rat tissues
Glands of the rat ventral prostate were quickly excised, weighed and quickly frozen in dry ice. Immunohistochemistry experiments were performed in contiguous cryostatic sections of 14 m thickness for direct comparison of tissue morphology, clusterin expression and localization of apoptosis by the TUNEL assay. For total RNA extraction and Western blot analysis, rat ventral prostates from 4 to 6 animals were pooled.

Analysis of the proliferation of BPH cells
For all cell proliferation assays, 4 × 10 4 BPH cells were inoculated into 12-well plates in their growth medium, starved in serum-free, red medium containing 0.1% BSA for 24 h, and then treated with specific stimuli for 48 h. The cells in a phenol-based, serum-free red medium containing 0.1% BSA were used as controls. Then the cells were trypsinized, and each experimental point was derived from a hemocytometer count, averaging at least six different fields for each

<Desc / Clms Page number 24>

 well, as previously reported (see Crescioli C, et al., Journal of Clinical and Endocrinology Metabolism (2000) 85: 2576-2583). The experiments were carried out using increasing concentrations (10-la to 10-7 M) of calcitriol or compound A with or without a fixed concentration of T (10 nM), KGF or Des (1-3) IGF- I (10 ng / ml). Growth assays were also performed using a fixed concentration of androgens (10 nM) with or without compound A (1 nM, 10 nM) or anti-androgenic finasteride (F, 1 nM) and cyproterone (Cyp, 100 nM). Growth assays were also performed using a fixed concentration of T (10 nM) or GF (10 ng / mL) with or without compound A (10 nM). In the same experiment, each experimental point was repeated in three or four copies and the experiments were carried out 3 times. The results are expressed in% of the variation (mean SEM) with respect to the maximal stimulation induced by T or GF.

In situ Terminal Marking (ISEL)
ISEL was performed on BPH cells using peroxidase from Apop Tag Apoptosis In Situ Detection Kit following the manufacturer's instructions. The cells were incubated with T (10 nM), KGF (10 ng / ml) or Des (1-3) IGF-I (10 ng / ml) with or without Compound A (10 nM). The percentage of apoptotic cells (the number of stained cells divided by the total number of cells) was calculated in at least five fields separated by slide in five different slides. The results are expressed as mean SEM of three separate experiments.

Inhibition test of 5-a-reductase
The assay for 5-a-reductase inhibition was performed using 5aR-1 transfected CHO 1827 cells or 5aR-2 transfected CHO 1829 cells as described (see Guarna A, and Journal of Medicinal Chemistry (2000) 43 3718-3735). Compound A was added in a range of

<Desc / Clms Page number 25>

 concentration ranging from 10-9 to 10-5 M, using finasteride as a control inhibitor in each experiment.

Link test
The binding assays on cytosol fractions of BPH fragments were performed as previously described (see Crescioli C et al.

Endocrinology (2003) 144 p 3046-3057), (final concentration of protein: 1.8 mg / ml). Incubations of the cytosolic fractions were carried out with increasing concentrations (0.125, 0.55, 0.5.1 nM) of [3H] -R1881 (specific activity: 83.5 Ci / mmol) in the absence or presence ([3H] -R1881: 1 nM) increasing concentrations of cold R1881 (10-10 to 10-6 M), DHT (10-10 to 10-6M), T (10-10 to 10-6M) , bicalutamide (10-10 to 10-4 M), and compound A (10-10 to 10-4M). To prevent the attachment of R1881 to the progesterone receptor, 1 M triamcinolone acetonide was added to each tube. Separation of bound and unfixed ligand was performed as previously described (see Crescioli C et al., Endocrinology (2003) 144 p 3046-3057). The protein content was determined by the known Bradford method, using BSA as a standard.

Luciferase test
PC3 cells stably transfected with human AR were transferred to 24 well plates with a density of 2 x 10 4 in Ham F12 medium plus 10% FCS. After 24 hours, the cells were transfected with 750 ng / well of plasmid pLSPP containing the wild type sequence configuration of the MMTV-LTR attached to the firefly luciferase gene (see Pazzagli M. et al., Analytical Biochemistry (1992)). 204 p 315-323.), Using lipofectamine 2000 (1 mg / ml) according to the manufacturer's instructions. After 48 h, the cells were incubated with DHT (10-12 to 10-6 M) or bicalutamide (10-9 to 10-5 M), in the presence of 3 nM DHT, and with an equimolar concentration of compound A for 18 h. Steroids and the analog

<Desc / Clms Page number 26>

 Compound A were dissolved in ethanol. Transfected cells incubated with ethanol only served only as positive controls.

 The luciferase assay was performed using a Berthold luminometer according to the manufacturer's instructions (Luciferase Assay System, Promega, Milan, Italy). The cells were lysed directly in the plate with 200 μl of lysis buffer solution.

Luciferase activity was measured on 20 μl of cell lysate for 10 s after the addition of 100 μl of luciferin. Total protein measurement was performed on 20 μl of cell lysate. At least three independent analyzes have been made in two copies.

Results
Incubation of BPH cells with increasing concentrations of calcitriol or compound A inhibits cell growth (Panel A, Figure 1).

Both compounds inhibit cell proliferation as a function of dose. ALLFIT analysis (see De Lean A, et al., American Journal of Physiology (1978) 235 p E97-E102) indicated that although maximal inhibition of calcitriol and compound A ("Cmpd A" in the figures ) was not statistically significantly different (Imax = 43 1%), their relative activity was, compound A being several log units more efficient than calcitriol, (-logICso of compound A = 15.8 ~ 0.3 report to -logICso calcitriol = 10.2 0.6, P <0.005).

 The proliferation of BPH cells was significantly increased (P <0.01) by testosterone (T) (156 ~ 8%), and growth factors (GF), such as (1-3) IGF- I (194%) or KGF (183%).

When cell growth was stimulated for 48 hours with T or GF (FIG. 1, panel B), the inhibitory effect of compound A was even more pronounced (Imax = 66.6 ~ 7.3%). Mathematical modeling (see De Lean A, et al., American Journal of Physiology (1978) 235 p E97-E102) of the inhibition curves a

<Desc / Clms Page number 27>

 indicated that Compound A was more potent in T-stimulated BPH cells (-logICsos = 16.4 ~ 0.6) than with the other two growth factors (logIC50s = 12, 7 0.6, and - logICso = 14.2 0.6 for (1-3) IGF-I and KGF, respectively, P <0.0001).

 Compound A (1 nM) antagonized proliferation of HBP cells stimulated not only by T but also by DHT to a similar extent to AR antagonist cyproterone acetate (Cyp, 100 nM; B). Conversely, finasteride 5-a-reductase inhibitor (F, 1 nM) antagonized only T-induced cell growth (Figure 2, panel A). In addition, compound A reduced growth even in cells not stimulated with androgen (Figure 2, panel A).

 To evaluate the potential anti-androgenic properties of compound A, in addition to inhibiting the growth of BPH cells, we investigated its interaction with AR. First, we eliminated the possibility that compound A binds to RA by performing competitive studies in human homogenates of BPH, using synthetic androgen [3H] -R1881 as a labeled ligand .

LIGAND analysis (see Munson PJ et al., Analytical Biochemistry (1980) 107 p 220-239,) data indicated that unlabeled R1881, DHT, T, and AR antagonist bicalutamide completely displaced the binding of 3H] -R1881 (Table I). Conversely, compound A did not compete with [3H] R1881 uptake at any concentration examined (Table I). These results were confirmed and prolonged using a luciferase reporter gene assay. In PC3 cells expressing full-length AR coupled with a luciferase reporter gene, DHT stimulated a dose-dependent increase in luciferase activity (ECso = 2, 1.3 nM, panel A), while the bicalutamide inhibited DHT-stimulated activity (ICso = 194 ~ 80 nM, panel B). In this system, the

<Desc / Clms Page number 28>

 Increasing concentration of compound A neither stimulated nor inhibited the increase in AR-induced luciferase activity (Figure 3). Finally, to verify whether compound A interacts with the formation of DHT, the active metabolite of T, we performed experiments in CHO cells transfected with 5-a-reductase type 1 and type 2. The results were compared with those obtained with finasteride (F).

While F inhibited the conversion of T to DHT with the expected IC50s, (ICso for 5-a-reductase type 1 = 659,100 nM and IC50 for 5-a-reductase type 2 = 53.7 ~ 11nM, n = 3). Compound A did not interfere with either isoenzyme up to the micromolar range (data not shown).

<Tb>
<Tb>

<SEP> Ligand of AR <SEP> Constants <SEP> of Affinity
<tb> (Kd <SEP> nmol / L)
<tb> R1881 <SEP> 0.16 <SEP> ~ <SEP> 0.06
<tb> DHT <SEP> 0.07 <SEP> ~ <SEP> 0.03
<tb> T <SEP> 1.89 <SEP> ~ <SEP> 0.94
<tb> Bicalutamide <SEP> 159 <SEP> + <SEP> 82
<tb> Compound <SEP> A <SEP>><SEP> 100,000
<Tb>
Table I androgenic agonist affinity constants (R1881, DHT, T), antagonist (bicalutamide) and compound A in human homogenates of BPH as detected by [3H] R1881 binding
The effect of compound A in BPH cells was, at least in part, due to the activation of programmed cell death as detected by the ISEL test (n = 3, Table II). The percentage of apoptotic nuclei increased significantly (270%) after 48 h exposure to compound A at 10 nM (P <0.01 vs control). Conversely, treatment with T (10 nM), or GFs (10 ng / ml) significantly reduced (P <0.01) the number of apoptotic BPH cells compared with the cells.

<Desc / Clms Page number 29>

 untreated (1-3 (1-3) IGF-I = -42%, KGF = -54%, T = -27%). However, even in the presence of GFs or T, compound A induced a sustained (over 250%) and significant (P <0.01) increase in the number of ISEL-positive HBP cells.

Apoptotic index (%)

<Tb>
<tb> Control <SEP> Compound <SEP> A
<tb> Control <SEP> 18.55 <SEP> ~ <SEP> 0.8 <SEP> 68.44 <SEP> ~ SEP> 1.26a
<tb> Of (1-3 <SEP> IGF-I <SEP> 10, <SEP> 69 <SEP> ~ <SEP> 0, <SEP> 6a <SEP> 45.85 <SEP> ~ <SEP> 0 , 66a, <SEP> b, <SEP> c
<tb> KGF <SEP> 8, <SEP> 5 <SEP> ~ <SEP> 0.42a <SEP> 44, <SEP> 46 <SEP> ~ <SEP> 0.57a '<SEP> b, <SEP > c
<tb> T <SEP> 13.56 <SEP> ~ <SEP> 0.72a <SEP> 49.06 <SEP> ~ SEP> 1.87a, <SEP> b, <SEP> c
<Tb>
Table II Effect of compound A (10 nM), GFs (10 ng / ml) or T (10 nM) on DNA fragmentation in BPH cells. The apoptotic index (%) represents the number of stained nuclei, as detected by ISEL, on all BPH cells in each of at least 5 separate fields per slide. The results are averaged ~ SEM in three separate experiments. Compound A can induce apoptosis in untreated BPH cells as well as in BPH cells incubated simultaneously with GFs or T (a: P <0.01 versus control; b: P <0.01 by compared to cells treated with compound A, c: P <0.01 compared to cells treated with GF or T).

Example 2: Antiproliferative Properties of Compound A in In Vivo Prostate Growth Models Protocols Involving Animals
Male Sprague Dawley rats (28 days old) were purchased from Charles River Laboratories (Calco, Lecco, Italy). All the described animal experiments have been carried out in accordance with accepted standards for animal health. Castration was performed scrotally under anesthesia with a ketamine / xylazine mixture. Three days after castration, rats (5-8 animals per group) were

<Desc / Clms Page number 30>

 treated or not with T-enanthate (30mg / kg) by two separate subcutaneous injections per week. The rats were orally treated for 5 days the first week, and 4 days the second week with a vehicle (miglyol 812), compound A (10.30, 100 and 300 g / kg) or finasteride (10 and 40 mg / kg) for a total of 9 administrations, and sacrificed a day later.

 Alternatively, intact adult male rats, Sprague Dawley (weight 250 g) were treated orally with vehicle (miglyol 812), compound A (10.30, 100 and 300 g / kg) or finasteride (10 and 40 mg). / kg) 5 days / week for 5 consecutive weeks and for two additional days the 6th week, for a total of 27 administrations, unless otherwise indicated. Blood for measurements of calcium and hormone content was obtained at the end of each experimental protocol.

Northern analysis of hybridization
Total RNA was extracted using RNAFast obtained from Molecular System (San Diego, CA). Fingerprinting, labeling, hybridization and probes (full-length clusterin cDNA of 1, 5 Kb and full-length cDNA of GAPDH 1, 2 Kb) were performed according to published procedures (Bettuzzi et al. Biochemical Journal, (1989), 257, p 293-296 and Marinelli et al., Biochemistry and Cell Biology, (1994), 72, pp. 515-521). Quantification of autoradiograms was obtained by densitometric scanning using an LKB Ultrascan XL densitometer.

immunohistochemistry
All cryostatic sections obtained from controls and treated rats were transformed into parallel as previously described (Astancolle et al., Journal of Endocrinology, (2000), 167, p 197-204). For each experimental condition, 3 alternating sections of 3 different rat prostates were examined. Negative checks, carried out

<Desc / Clms Page number 31>

 excluding the specific antibody of the reaction, showed no specific staining. Contrecoloration was performed with hematoxylin, and coverslips were mounted with Eukitt (0.

Kindler GmbH and Co, Germany). High-power color digital images were acquired by a CCD camera through the microscope.

In situ DNA fragmentation analysis (TUNEL)
DNA fragmentation in the cryostatic sections of the prostate, as assessed by the TUNEL endpoint deoxynucleotidyl transferase (TdT) labeling assay, was performed using the in situ cell death detection kit (POD, Roche) as the manufacturer recommends. TUNEL positive apoptotic nuclei have been documented by high magnification color digital images acquired by a CCD camera through the microscope. Counterstaining was performed with eosin, and coverslips were mounted with Eukitt (0 Kindler Gmbh and Co., Germany).

Calcium measurements
Serum calcium levels were measured using a commercially available colorimetric assay (Sigma) according to manufacturers' instructions.

Measurement of testosterone and rLH
Serum levels of T and rLH hormones were determined using commercially available radioimmunoassay kits, according to manufacturers' instructions. To measure the serum T level in rats, the samples were first added to 4 volumes of diethyl ether, mixed by gentle inversion for 15 min and then centrifuged for 5 min at 2000 rpm. The aqueous phase was frozen in dry ice and the organic phase was collected and evaporated to dryness under a stream of nitrogen. The dry extract was reconstituted in the assay buffer solution as

<Desc / Clms Page number 32>

 follows: (1 vol: 1 vol) in intact rats, and (4 vol: vol) in castrated rats.

Statistical analysis
Statistical analysis was performed by one-factor ANOVA and by paired or unpaired Student t-tests, if appropriate. The binding data was analyzed using the LIGAND computer program (Munson et al., Analytical Biochemistry, (1980), 107, p 220-139).

 The ALLFIT computer program (De Lean et al., American Journal of Physiology, (1978), 235, p. E97E102) was used for the analysis of sigmoidal dose-effect curves to obtain estimates of half-maximal values. inhibition (IC50) and values corresponding to half of the maximal stimulation (ECso) as well as the effects of maximal inhibition (Imax) and maximal stimulation (Emax). Data were expressed in (mean ~ SEM).

Results
In order to examine the anti-proliferative properties of compound A on models of prostate growth in vivo, castrated and intact rats were orally treated with increasing concentrations of Compound A (10 to 300 g / kg) or finasteride (F) (10, 40 mg / kg). As shown in Figure 4, panel A, castration significantly reduced the weight of the ventral prostate, whereas a two-week treatment with testosterone enanthate (T) (30 mg / kg) not only completely restored but also stimulated its growth. Compound A, at any dose tested, completely blunted the T-stimulated prostate overgrowth, reducing the weight of the ventral prostate to a lower value than untreated rats. Similar results were obtained with finasteride (10, 40 mg / kg). A one-month treatment on intact adult rats with Compound A significantly decreased the weight of the ventral prostate, with

<Desc / Clms Page number 33>

 a maximum reduction (30%) at the highest dose tested (300 g / kg). At this dose, the inhibitory effect of compound A on prostate growth was comparable to that induced by 10 or 40 mg / kg of finasteride (Figure 4, panel B). In all experimental protocols, oral administration of different doses of compound A caused very modest hypercalcemia only at the highest dose tested (300 g / kg) (Table III). No other perceptible side effects were observed.

Serum Calcium
Witness 10.2 ~ 0.16
Compound A 10 g / kg 10.16 0.24
Compound A 30 g / kg 9.87 0.15
Compound A 100 g / kg 10.55 0.18
Compound A 300 g / kg 10.85 0.1 Table III Calcium (mg / dl) in castrated rats in which T has been replaced after different doses (10, 30, 100, 300 g / kg) of compound A. Compound A never varied serum calcium levels in castrated rats in which T was replaced by T-enanthate (30 mg / kg / week) compared to controls. Similar results were obtained in intact rats (not shown). The results represent the mean ~ SEM of the rats / group.

 In order to better understand the molecular mechanisms responsible for the reduction of compound-induced prostate weight, clusterin and protein gene expression and the morphological characteristics of apoptosis were evaluated by the TUNEL test. labeling with terminal deoxynucleotidyl transferase (TdT). Clusterin is an ubiquitous gene strictly related to cell cycle arrest and atrophy, the expression of which is reduced by androgens. Figure 5, panel A, shows the prostate expression of mRNA

<Desc / Clms Page number 34>

 clusterin, as detected by Northern analysis, in orchidectomized rats to which T was added or not. Castration significantly increased Clusterin mRNA abundance, whereas this effect was completely reversed by a two-week T administration. Simultaneous treatment with different concentrations of Compound A (300 and 100 g / kg) or of F (40 mg / kg) partially blunted the decrease in T-induced clusterin gene expression. In intact rats (Figure 5, panel B), one-month administration of different concentrations of compound A (30 and 100 μg / kg) induced a sustained increase in clusterin gene expression in the prostate, comparable to, or even greater than, that induced by 40 mg / kg F.

 The local expression of clusterin in the prostate of orchidectomized rats is shown in Figure 6. Castration induced marked and widespread atrophy in the prostate gland, and almost all cuboidal epithelial cells adjoined to the lumen of the gland were clusterin positive (panel A). Replacement of T (panel B) reversed the morphological features of atrophy and uniformly reduced clusterin staining. Such an effect was avoided by the simultaneous administration of compound A (panels C and E). Panel D and F show TUNEL test results in sections adjacent to those shown in panels C and E. Treatment with compound A (100 g / kg, panel D and 300 g / kg, panel F) induced nuclear fragmentation evident in epithelial and stromal cells, and apoptosis was detectable in both positive and clusterin negative cells. The first two panels of Figure 7 show the morphology of the prostate gland of intact rats treated for clusterin detection, with (panel A) or without (panel B) omission of the primary antibody. It should be noted that clusterin labeling is almost absent in the prostate

<Desc / Clms Page number 35>

 untreated adult rats (panel B) because it is a nuclear fragmentation (TUNEL, panel C).

Conversely, treatment with different doses of compound A induced the expression of clusterin (panels D to F) and apoptosis (C, G and I). Panel F compares the effect of finasteride (40 mg / kg) on clusterin positivity in the prostate gland.

 In order to eliminate the possibility that Compound A reduces prostate growth in vivo by interfering with pituitary or testicular function, serum levels of rat luteinizing hormone (rLH) and T were measured in castrated rats and intact. As expected (Table IV, panel A), castration significantly reduced T while increasing serum levels of rLH. Administration of T enanthate (30mg / kg) (two weeks) completely reversed the effect of orchiectomy. Oral treatment with compound A (100 and 300 g / kg) of castrated rats in which T was replaced did not significantly affect serum levels of rLH or T. Similar results were obtained in rats intact (Table IV, panel B). In fact, chronic administration (1 month) of compound A (10, 30,100 g / kg) or F (40 mg / kg) to intact rats did not alter serum levels of rLH and T.

<Desc / Clms Page number 36>

<Tb>
<Tb>

Panel <SEP> A
<tb> rLH <SEP> T
<tb> control <SEP> (intact <SEP> rats) <SEP> 2.36 <SEP> + <SEP> 0.46 <SEP> 11.5 <SEP> ~ <SEP> 2.44
<tb> castrated <SEP> 20.64 <SEP> ~ <SEP> 6 <SEP> 0.9 <SEP> ~ <SEP> 0.32 <SEP> *
<tb> castrated <SEP> + <SEP> T <SEP> replaced <SEP> 2.08 <SEP> 0.36 <SEP> 21.25 <SEP> ~ <SEP> 4.12
<tb> castrated <SEP> + <SEP> T <SEP> replaced <SEP> + <SEP> 1.8 <SEP> ~ <SEP> 0.2 <SEP> 11.13 <SEP> ~ <SEP> 1 02
<tb> compound <SEP> A <SEP> 100 <SEP> gg / kg
<tb> castrated <SEP> + <SEP> T <SEP> replaced <SEP> + <SEP> 3.15 <SEP> ~ <SEP> 0.65 <SEP> 15.73 <SEP> ~ <SEP> 2 75
<tb> compound <SEP> A <SEP> 300 <SEQ> gg / kg
<tb> Panel <SEP> B
<tb> rLH <SEP> T
<tb> control <SEP> (intact <SEP> rats) <SEP> 2 <SEP> ~ <SEP> 0.16 <SEP> 11.98 <SEP> ~ <SEP> 2.8
<tb> 7
<tb> Finasteride <SEP> 2.2 <SEP> ~ <SEP> 0.4 <SEP> 18.11 <SEP> ~ <SEP> 3.2
<tb> 3
<tb> Compound <SEP> A <SEP> 10 <SEP> g / kg <SEP> 2.22 <SEP> 0.25 <SEP> 19.13 <SEP> 3.8 <SEP>
<tb> 3
<tb> Compound <SEP> A <SEP> 30 <SEP> g / kg <SEP> 2.32 <SEP> ~ <SEP> 0.36 <SEP> 9.39 <SEP> + <SEP> 2
<tb> Compound <SEP> A <SEP> 100 <SEP> g / kg <SEP> 1.96 <SEP> ~ <SEP> 0.13 <SEP> 11 <SEP> ~ <SEP> 2.14
<Tb>
Table IV Serum levels of rLH (ng / ml) and T (nM) in castrated rats in which T (panel A) or intact (panel B) were replaced after treatment with different doses of compound A.

Panel A. Castration significantly reduced serum T (* P <0.01 compared to control) while increasing serum rLH (* P <0.05 compared to control) .

After treatment with T-enanthate (30mg / kg / week) serum levels of rLH and T were restored. Compound A at all doses tested did not significantly affect serum levels of rLH or T.

Panel B. Chronic administration (1 month) of F (40 mg / kg) or compound A (10.30 and 100 g / kg) did not affect serum rLH or serum T in intact rats.

<Desc / Clms Page number 37>

 This study demonstrates that Compound A reduces prostate size in intact rats to a degree similar to finasteride. In addition, like finasteride, compound A suppresses the proliferative activity in vitro and in vivo of testosterone.

However, unlike finasteride, compound A does not inhibit the activity of 5-a-reductase type 1 or type 2 and can prevent the growth of BPH cells induced not only by T but also by DHT. These anti-androgenic properties of compound A are independent of the interaction with AR, as shown by the fact that compound A can not bind to RA, and can not act as an AR agonist or antagonist in PC3 cells transfected with AR.

In addition, compound A did not affect the secretion of sex hormones because, in rats, plasma levels of gonadotropin and T were unchanged by daily administration of compound A for up to one month. Therefore, compound A acts downstream of the interaction between ligand and AR receptor. Without wishing to be bound by the theory this action most likely occurs through the interruption of the relay between testosterone and growth factor.

 Very low concentrations of Compound A were able to completely prevent not only T-stimulated BPH cell proliferation, but also proliferation induced by the two most important intraprostatic growth factors: IGF-I and KGF. In addition, even in the presence of T or GFs, compound A induced apoptosis in BPH cells. Compound A-induced cell death program also appeared in the prostate both intact and orchidectomized rats in which T was replaced and was characterized by a diffuse appearance of DNA fragmentation with increased concomitant expression of clusterin gene and protein. Clusterin is a protein tightly regulated in the prostate by

<Desc / Clms Page number 38>

 androgens (Bettuzzi et al., Biochemical Journal, (1989), 257, p 293-296). Although clusterin function is still not well understood, it is markedly increased under atrophic conditions of the gland (Bettuzzi et al., Oncogene, (2002), 21, p 4328-4334 and Bettuzzi et al. Journal of Endocrinology, (1992), 132, p 361-367) and apoptosis (Leskov et al., Journal of Biological Chemistry, (2003), 278, p 11590-11600). Thus, the induction of clusterin by treatment with compound A is consistent with the ability of this compound to inhibit proliferation and induce apoptosis in prostate cells.

 In conclusion, this study indicates that Compound A is effective in reducing prostate cell growth in different experimental models.

Example 3: Reduction of prostate weight in healthy dogs treated with compound A.

 A nine-month toxicity study was conducted in four groups of male Beagle dogs, which were treated daily with oral gavage with 0.5 g, 1.5 g and 5 g / kg body weight / day of compound A ( in the vehicle Miglyol 812) or with the vehicle alone. This treatment was followed by a two-month cure period for the highest dose group, 5 g, after which the prostate weight was measured. In addition to the entirely favorable toxicity data, a lower prostate weight was observed at the end of treatment with compound A (see FIG. 8) and after healing (see FIG. 9). Healing results were statistically analyzed using a one-tailed Student's t test and found to be significantly different between compound A and the vehicle (P <0.05). These results further demonstrate the ability of compound A to reduce prostate size in vivo.

<Desc / Clms Page number 39>

Example 4: Soft gelatin capsule as an oral dosage form
A capsule for oral administration is formulated under nitrogen and in orange light from 0.01 to 25.0 mg of compound A in 150 mg of fractionated coconut oil (eg, Miglyol 812), with 0.015 mg of butylated hydroxytoluene (BHT) and 0.015 mg of butylated hydroxyanisole (BHA), filled into a soft gelatin capsule.

The capsule is prepared using the following method:
1. BHT and BHA are suspended in fractionated coconut oil (e.g., Miglyol 812) and heated to about 50 ° C with stirring until dissolved.

 2. Compound A is dissolved in the solution of step 1 at 50 ° C.

 3. The solution in Step 2 is cooled to room temperature.

 4. The solution from Step 3 is poured into soft gelatin capsules.

 All manufacturing steps are performed under a nitrogen atmosphere and protected from natural light.

Example 4A Soft Gelatin Capsule as Oral Galenic Form
A capsule intended for oral administration is formulated under nitrogen and in an orange light.

150 g of compound A in 150 mg of fractionated coconut oil (Miglyol 812), with 0.015 mg of butylated hydroxytoluene (BHT) and 0.015 mg of butylated hydroxyanisole (BHA), filled into a soft gelatin capsule.

Example 4B: Soft gelatin capsule as an oral dosage form
A capsule for oral administration is formulated under nitrogen and orange light: 75 g of compound A in 150 mg of fractionated coconut oil (Miglyol 812), with 0.015 mg

<Desc / Clms Page number 40>

 of butylated hydroxytoluene (BHT) and 0.015 mg of butylated hydroxyanisole (BHA), filled into a soft gelatin capsule.

Example 5: Reduction of Prostate Weight in Human Clinical Trials
A randomized, double-blind, placebo-controlled, parallel-group study was performed to determine the effect of compound A (1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20 epi-cholecalciferol) in patients with BPH.

 The primary inclusion criterion was that male patients were diagnosed with BPH and had a prostate volume> 40 ml as determined by transrectal ultrasonography (USTR).

Statistical methods: The primary efficacy analyzes were performed on a population treated according to the protocol (Per-Protocol: PP) and, as a support, the same analyzes had to be made on the population to be treated. Patients who could be assessed by the protocol-based analysis were all randomized patients who adhered to the protocol criteria who followed the entire study without major protocol violations and who presented valid assessments of prostate volume. Valid patients for the population to be treated (TTIs) were all randomized patients who received at least one dose of the test drug and for whom the volume of the prostate at baseline and after 12 weeks was available.

 All randomized patients who took at least one dose of the study drug were evaluated for safety analysis.

 The comparability of the treatment group was assessed at baseline for all patients with descriptive significance. The data were processed by the chi-square test for the nominal variables, and by the ANOVA model for the continuous variables.

<Desc / Clms Page number 41>

 Descriptive statistics were calculated using standard methods: mean, standard deviation, minimum and maximum values on continuous variables, and absolute and relative frequencies for nominal variables. Descriptive statistics were made for each treatment and for each visit / week.

 Centers with fewer than 4 patients were pooled.

 The primary efficacy variable was the percentage change in prostate volume as measured by centralized MRI axial scanning. An ANOVA model was used for analysis, with treatment and center as fixed effects.

 Study participants received a 150 g capsule (according to Example 4A with the drug omitted in the case of placebo) once daily in the morning.

The duration of treatment was 12 weeks. The number of patients involved was as follows:

<Tb>
<tb> Compound <SEP> A <SEP> Placebo <SEP> Total
<tb> Patients <SEP> randomized <SEP> 57 <SEP> 62 <SEP> 119
<tb> Patients <SEP> with <SEP> accomplished <SEP> 56 <SEP> 60 <SEP> 116
<tb> the <SEP> treatment <SEP> (98.3 <SEP>%) <SEP> (96.8 <SEP>%) <SEP> (97.5 <SEP>%)
<tb> Patients <SEP> with <SEP> 0 <SEP> 2 <SEP> 2
<tb> interrupted <SEP> or <SEP> with <SEP> (3,2 <SEP>%) <SEP> (1,7 <SEP>%)
<tb> not <SEP> followed <SEP> the <SEP> treatment
<tb> Effect <SEP> Therapeutic <SEP> 1 <SEP> (1.8 <SEP>%) <SEP> 0 <SEP> 1
<tb> insufficient <SEP> (0.8 <SEP>%)
<Tb>
Percentage change in prostate volume measured by axial scanning
The percentage change in prostate volume in the PP population was -1.89 5.2 in the compound A group compared to 4.99 in the 5.99 placebo group with a significant p value <0 , 0001 in favor of compound A.

The difference between treatments (compound A minus placebo) was -7.24 with

<Desc / Clms Page number 42>

 95% confidence limit of -9.54 and -4.94. The effect of the center was also significant (p = 0.0176). The same analysis performed on the ITT population confirmed the results (p = 0001), that is, compound A was more effective than placebo in reducing prostate volume.

 In patients with a basal volume of the prostate> = 80 ml the difference between the treatment groups (p = <0.0001) was clearer compared with patients with a basal volume of the prostate <60 ml ( p = 0.0320) particularly in the PP population.

 In patients aged between 61 and 70 years, the difference between treatments, still in favor of compound A, was more obvious than with the treatments of older patients (age> 70 years). In fact, in the ITT population, the difference between treatments in patients> 70 years old had a significance of p = 0.0540 compared to p = <0.0001 for the other classes of patients.

answering Machines
The proportion of responders observed with compound A was 27.5%, in the PP population, with an unchanged proportion of 65% and only 7.5% of patients were not responders. In the placebo group the responder class was nil, in fact, the patients were equitably divided into a class of patients with no change and a class of responders (50% in each class). The chi-square test comparing the proportions confirmed the results observed for the primary efficacy variable, p = <0.0001, that is, compound A was more effective than placebo in reducing the volume. of the prostate.

 In the ITT population the results were confirmed, the proportion of responders in the group of compound A being 28.8%, with a p value determined by the chi-square test <0.0001 between treatments.

<Desc / Clms Page number 43>

 The mean reduction in prostate volume relative to baseline volume in responder patients was -6.88 2.5, in the PP population, while the mean difference in patients with no change was -0, 2.3 in the group of compound A versus 0.40 ~ 2.0 in the placebo group. For non-responder patients the mean difference was 3.93 0.8 in the group of compound A versus 7.48 ~ 4.9 in the placebo group, confirming the better efficacy of compound A for controlling and reduce the volume of the prostate.

Percentage change in prostate volume measured by paraxial scan and centralized transient
Support analyzes with paraxial and transient acquisition confirmed the results obtained with axial scanning. In particular, in the PP population, for paraxial acquisition the percentage change was-1.30 6.9 in the group of compound A versus 2.57 6.8 in the placebo group, p = 0 0172; while for the transient scan the percentage change was -0.22 ~ 9.6 for the group of compound A versus 6.18 ~ 10.9 for the placebo group, p = 0.0028.

Also, in the ITT population there was a significant difference between treatments in favor of compound A, regarding the reduction of prostate volume.

Total serum PSA and hormone levels
The mean change in PSA in the group of compound A was 0.23 1.3 compared to 0.43 1.7 in the placebo group for the PP population.

No significant difference was observed between treatments (p = 0.2722).

 Also, for testosterone, in the PP population, there was no significant difference between the groups (p = 0.2150), with an average change of 0.07 ~ 1.5 in the group of compound A versus at 0.22 1.4 in the placebo group.

<Desc / Clms Page number 44>

 There was no difference between the treatment groups for dihydrotestosterone (p = 0.7257 PP population), with a mean change observed in the PP population of -30.77 227.71 in the compound A group compared with at -166.76 490.26 in the placebo group.

 There was no difference in LH hormone (p = 0.9320 - PP population), with an average change in compound A of -0.02 ~ 1.7 compared to -0.1.8 in the group placebo for the PP population.

 Mean changes in PSA and hormone levels were around zero, except for DHT, compound A did not change hormone levels.

 The same results were confirmed in the ITT population.

safety
The number of patients with at least one adverse event was 31 (17 in the compound A group, 14 in the placebo group); no patient withdrew because of adverse events, and only one patient in the placebo group experienced a serious adverse event: acute cholecystitis, resolved by hospitalization.

 The number of patients with adverse events related to treatment with compound A was 3 (5.26%), while the number of patients with treatment-related adverse events was 6 (9.68%) in the group placebo. The events related to compound A were: dizziness, headache, decreased libido and hot flashes, while placebo-related events were: increased phosphate in the urine, headache, syncope, decreased libido (3 patients), hypercalciuria, erectile dysfunction and hot flushes.

 Calciuria values monitored over the entire duration of the study in the

<Desc / Clms Page number 45>

 Compound A did not differ significantly from the placebo group.

Conclusion
In this short study, which proves the concept of the effect of compound A on prostate size in patients with BPH, the drug has been shown to be effective. Analysis of the primary variable in the study, ie prostate size assessment, showed a significant difference between compound A and placebo, thereby confirming that the test drug can stop progression of the prostate. disease. The safety profile was good, there was no different incidence of adverse events between compound A and placebo, and no serious adverse events were reported in the group of compound A. The drug tested was free of any anti-androgenic effect, it had no effect on PSA levels, and had no significant effect on calcium homeostasis.

Example 6 The Activity of Compound A on the Growth and Function of Bladder Cells
Compound A has been shown to be effective in inhibiting basal growth of bladder cells and testosterone stimulated growth. This activity, which has never been reported before, is dose-dependent with 1.6 7 x 10-15 for 1-α-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo- 20-epi-cholecalciferol ("compound A" / "Cmpd A" in the figures) (on the stimulated cells) (see FIG. 10 and FIG. 11).

 This effect was significantly greater than that of anti-androgenic finasteride widely used in the treatment of urogenital diseases (Figure 11).

Example 7 The Effect of Compound A on Bladder Dysfunction in a Model of Bladder Collar Obstruction

<Desc / Clms Page number 46>

Experimental part 1. Materials 1.1. Animals: Sprague-Dawley female rats, weighing 200 to 250 g. 1. Group A group: BOO rats, treated with compound A for 2 weeks, starting one day after the creation of the obstruction (n = 12) Group B : BOO rats, treated with vehicle for 2 weeks, starting one day after creation of obstruction (n = 12) Group C: dummy rats treated with compound A for 2 weeks, starting one day after Surgery (n = 12) 1. 3. Studies: a) Cystometry (approximately 18 hours after the last administration of the drug / vehicle, 12 hours after removal of the obstruction ligature) in a conscious state. b) Measurements of the weight of the bladder c) In vitro studies 2. Methods 2. 1. Blockade of the bladder neck (BOO):
The bladder and ureterovesical junction were exposed through a lower mid-length abdominal incision. A 0.9 mm metal shank was placed next to the proximal urethra and a ligation with 3/0 silk thread was securely attached around the urethra and stem, which was subsequently removed. The fictitious surgical procedure was therefore performed without placing the ligature. After 13 days, the ligation was removed and a catheter was inserted into the bladder dome and implanted subcutaneously.

2. 2. Cystometry
The morning after insertion of the catheter, a cystometric examination was performed without any anesthesia or stress in a metabolic cage. The

<Desc / Clms Page number 47>

 The amount of urine evacuated was measured using a liquid collector connected to a force displacement transducer. The bladder was continuously filled with saline at room temperature. The catheter was also connected to a pressure transducer. After a stabilization period of 30 to 60 min, when the evacuation models were reproducible, the following parameters were recorded for 30 min: pressure at the base of the bladder, urination pressure, threshold pressure, interval and volume urination, and bladder contractions. The amount of post-voiding residue was manually studied 3 times at the end of the cystometry. The capacity of the bladder was calculated on the basis of the measured values.

2. 3. In vitro studies 2. 3.1. Preparations
Once cystometry was complete, the rats were sacrificed by carbon monoxide asphyxiation followed by exsanguination. The abdomen was examined by a lower incision of intermediate length after which the symphysis was opened. The bladder was carefully dissected freely, and immediately placed in a minced form in Krebs solution, and band preparations were dissected.

3.2 Recording of mechanical activity
The bladder and urethra were separated at the bladder neck, and semicircular bands were prepared from the middle third of the detrusor (1 x 2 x 5 mm). All preparations were used immediately after removal.

 The strips were transferred to 5 ml tissue baths containing the Krebs solution. The Krebs solution was maintained at 37 ° C. and continuously sparged with a mixture of 95% O 2 and 5% CO 2, resulting in a pH of 7.4. The strips were suspended between two L-shaped hooks with a silk thread ligation. A hook has been connected to a mobile unit allowing adjustment of the

<Desc / Clms Page number 48>

 passive voltage, and the other to a Grass FT03C force transducer (Grass Instruments Co, MA, USA). The isometric tension was recorded using a Grass polygraph (7D). After mounting, the strips were stretched at a passive tension of 4 mN (the same voltage for all preparations) and allowed to return to equilibrium for 45-60 min before the other experiments were performed.

2. 3.3. Electric stimulation
Electrical stimulation (EFS) was accomplished using two platinum electrodes placed on either side of the preparations, and was performed using a Grass S48 or S88 stimulator, providing simple square pulses at selected frequencies. The duration of the stimulus train was 5 s, the pulse duration 0.8 ms, and the stimulation interval 2 min. The polarity of the electrodes was reversed after each pulse using a polarity change unit.

2. 3.4 Process
Each experiment was started by exposing the preparations to a high K + K + solution (124 mM) until two reproducible contractions were obtained. Then, the following experiments were performed: a) Electrical stimulation on the nerves was performed and the frequency response was obtained in the presence and absence of atropine. b) Concentration-response curves were plotted for carbachol and ATP.

Results
The validated model of rat bladder neck obstruction described above was used to examine the ability of compound A to control and treat bladder dysfunction. The objective was to evaluate whether an analogue of vitamin D3 (1- [alpha] - fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epicholecalciferol - compound "A" at 150 g / kg / daily) may prevent hypertrophy

<Desc / Clms Page number 49>

 bladder and bladder dysfunction such as overactive bladder.

 In this model, a ligation was surgically placed around the neck of the catheterized bladder, so that when the catheter was removed, the bladder experienced increased urethral resistance. Rats underwent continuous cystometry to evaluate bladder function. In addition, the contractile properties of an isolated bladder preparation in response to nerve stimulation and exogenous stimuli in vitro were studied under electrical stimulation (EFS).

 The following cystometric parameters were examined (see Figures 12 to 16): - the pressure of urination (the maximum pressure of the bladder during urination), - the capacity of the bladder (the residual volume after evacuation plus the volume of solution saline infused to induce evacuation), - volume of urination (volume of urine expelled) - post-void residue (bladder capacity minus volume of urination) and - frequency and magnitude of changes spontaneously intervening intravesical pressure (vesical contractions).

In this model, the evaluated analogue has a beneficial effect on bladder function. This effect was evident in the normal bladder and is maintained in the obstruction of the bladder neck. In particular, significant differences with respect to the vehicle were observed for: the frequency and amplitude of spontaneous bladder contractions (FIGS. 13 and 14); the post-voiding residue (absent with compound A, FIG. 16); - the pressure of urination (Figure 15);
In addition, a beneficial effect on bladder function has been confirmed in in vitro tests:

<Desc / Clms Page number 50>

 - answer K; response to EFS (Fig. 17); - response to carbachol.

 Finally, a slight decrease in the weight of the bladder was observed with compound A (FIG. 12).

 These data demonstrate the use of compound A (in the dose range of 50 to 300 g corresponding to approximately 0.725 to 5 g / kg of body weight in humans) for the prevention and treatment of bladder dysfunction, for example, overactive bladder, as, for example, demonstrated in patients with BPH.

Abbreviations T: testosterone DHT: dihydrotestosterone GF: growth factor BPH: benign prostatic hyperplasia PP: according to ITT protocol: to be treated ANOVA: analysis of variance USTR: transrectal ultrasonography BOO: bladder neck obstruction AR: receptors androgens PSA: Prostate-specific antigen
All references including the patents and patent applications cited in this application are incorporated herein by reference in order to cover the widest possible range.

 In the entirety of the description and the claims that follow, unless the context indicates a different meaning, the word "includes", and its variations such as "include" and "comprising" will be understood to imply the inclusion of 'an integer or a step or group of integers but not the exclusion of any other integer or step or group of integers or steps.

 The request for priority may be based on the application of which the present description and

<Desc / Clms Page number 51>

 The claims are in accordance with any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may be in the form of a product, composition, process, or use of the claims and may include, by way of example and without limitation, the following claims.

Claims (23)

 1. Use of 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the prevention and / or treatment of benign prostatic hyperplasia. Use according to claim 1 wherein the medicament is administered separately, sequentially or simultaneously in separate pharmaceutical formulations or in combination with a second active agent against BPH. 3. Use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, in combination with a second active agent against BPH for the manufacture of a medicament for the prevention and / or treatment of benign prostatic hyperplasia. Use according to claim 2 or claim 3 wherein the second active agent against BPH is an α-adrenergic receptor blocking agent. The use of claim 4 wherein the α-adrenergic receptor blocking agent is selected from terazosin, doxazosin, tamsulosin, silodosin. Use according to claim 2 or claim 3 wherein the second active agent against BPH is a 5-α-reductase inhibitor. <Desc / Clms Page number 53> The use of claim 6 wherein the 5-a-reductase inhibitor is selected from finasteride and dutasteride. A pharmaceutical formulation comprising 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol, or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier intended for the prevention and / or treatment of benign prostatic hyperplasia. A packaged formulation comprising a pharmaceutical composition comprising 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier packaged with instructions for use in the prevention and / or treatment of benign prostatic hyperplasia. Use according to any one of claims 1 to 7 wherein the 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol, or a pharmaceutically acceptable salt or ester of it, is provided as a unit dose. A formulation according to claims 8 or 9 wherein 1-α-fluoro-25-hydroxy-16,23E-diene-26,27bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof , is provided as a unit dose. The formulation of claims 8, 9 and 11 further comprising a second active agent against BPH. <Desc / Clms Page number 54> 13. Use according to claim 10 wherein the unit dose of 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol is 50 to 150 g. 14. Use according to any one of claims 1 to 7 or 10 or 13 for the prevention and / or treatment of benign prostatic hyperplasia without anti-androgenic adverse effects in the prostate and outside of the prostate. 15. Use according to any one of claims 1 to 7 or 10,13 or 14 for the prevention and / or treatment of benign prostatic hyperplasia with prevention and / or concomitant treatment of bladder dysfunction. . 16. A pharmaceutical formulation comprising 1-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epicholecalciferol dissolved in fractionated coconut oil and one or more preservatives. The formulation of claim 16 wherein the fractionated coconut oil is Miglyol 812. The formulation of claim 16 or claim 17 wherein the preservatives are selected from butylated hydroxytoluene, butylated hydroxyanisole and mixtures thereof. A formulation according to claim 8, 11, 12 or 16 to 17 which is presented in capsule form. 20. 1-α-Fluoro-25-hydroxy-16,23E-diene-26,27-bishomo- 20-epi-cholecalciferol or a pharmaceutically acceptable salt or ester thereof, for use in the prevention and control of / or the treatment of benign prostatic hyperplasia. <Desc / Clms Page number 55> 21. 1-α-Fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol or a pharmaceutically acceptable salt or ester thereof, for use in the prevention and control of / or the treatment of benign prostatic hyperplasia without anti-androgenic effects in the prostate and outside the prostate. 22. 1-α-Fluoro-25-hydroxy-16,23E-diene-26,27-bishomo- 20-epi-cholecalciferol or a pharmaceutically acceptable salt or ester thereof, for use in the prevention and control of / or the treatment of benign prostatic hyperplasia with prevention and / or concomitant treatment of bladder dysfunction. 23. The formulation of claim 11 wherein the unit dose of 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol is 50 to 150 g.